相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma
Jilong Yang et al.
CANCER LETTERS (2010)
Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma
Ivan Pasic et al.
CANCER RESEARCH (2010)
Fluorescent In Situ Hybridization As a Primary Test for HER2 Status in Breast Cancer: Controversies
Vincenzo Arena et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Novel therapeutic agents for osteosarcoma
Kathleen O'Day et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
LSAMP, a Novel Candidate Tumor Suppressor Gene in Human Osteosarcomas, Identified by Array Comparative Genomic Hybridization
Stine H. Kresse et al.
GENES CHROMOSOMES & CANCER (2009)
Fluorescent In Situ Hybridization for Human Epidermal Growth Factor Receptor 2 Assessment in Breast Cancer: Is It Applicable As a Primary Test?
Vincenzo Arena et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts)
Wei-Lien Wang et al.
MODERN PATHOLOGY (2009)
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
E. S. Rennel et al.
BRITISH JOURNAL OF CANCER (2008)
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
Serena S. Freeman et al.
CANCER (2008)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Hypoxia markers in human osteosarcoma:: An exploratory study
Hiroo Mizobuchi et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2008)
Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays
Brenda Summersgill et al.
NATURE PROTOCOLS (2008)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Weighted clustering of called array CGH data
Wessel N. Van Wieringen et al.
BIOSTATISTICS (2008)
Cloning of genetically tagged chromosome break sequences reveals new fragile sites at 6p21 and 13q22
Anne Fechter et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Markers of angiogenesis and clinical features in patients with sarcoma
Steven DuBois et al.
CANCER (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Anti-angiogenic therapy for osteosarcoma
Gerald M. Y. Quan et al.
CANCER AND METASTASIS REVIEWS (2006)
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity:: A joint study by the Italian and Scandinavian Sarcoma Groups
S Ferrari et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas - An immunohistomchemical and fluorescence in situ hybridization study
S Suzuki et al.
CANCER (2005)
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
XL Wan et al.
CANCER RESEARCH (2005)
Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1)
A Budde et al.
ONCOGENE (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
C Kersting et al.
LABORATORY INVESTIGATION (2004)
Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma
TK Man et al.
BMC CANCER (2004)
Prognostic relevance of increased angiogenesis in osteosarcoma
M Kreuter et al.
CLINICAL CANCER RESEARCH (2004)
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
M Zangari et al.
CLINICAL CANCER RESEARCH (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data
AB Olshen et al.
BIOSTATISTICS (2004)
High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays
JA Squire et al.
GENES CHROMOSOMES & CANCER (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling
R Humar et al.
FASEB JOURNAL (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)